Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to 0.56.

  • Theravance Biopharma's Equity Ratio rose 742.5% to 0.56 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.56, marking a year-over-year increase of 742.5%. This contributed to the annual value of 0.5 for FY2024, which is 1110.43% down from last year.
  • Per Theravance Biopharma's latest filing, its Equity Ratio stood at 0.56 for Q3 2025, which was up 742.5% from 0.53 recorded in Q2 2025.
  • Theravance Biopharma's 5-year Equity Ratio high stood at 0.73 for Q4 2022, and its period low was 0.99 during Q1 2021.
  • Over the past 5 years, Theravance Biopharma's median Equity Ratio value was 0.53 (recorded in 2025), while the average stood at 0.11.
  • Its Equity Ratio has fluctuated over the past 5 years, first crashed by 28139.41% in 2021, then surged by 18052.3% in 2022.
  • Theravance Biopharma's Equity Ratio (Quarter) stood at 0.9 in 2021, then soared by 180.52% to 0.73 in 2022, then decreased by 23.34% to 0.56 in 2023, then decreased by 11.1% to 0.5 in 2024, then rose by 12.99% to 0.56 in 2025.
  • Its last three reported values are 0.56 in Q3 2025, 0.53 for Q2 2025, and 0.48 during Q1 2025.